Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pharmacogenetics in mood disorder.

Charles U Nnadi1, Joseph F Goldberg, Anil K Malhotra

  • 1The Zucker Hillside Hospital, Glen Oaks, New York 11004, USA.

Current Opinion in Psychiatry
|April 28, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Co-expression-based models improve eQTL predictions for transcriptome-wide association studies and highlight new schizophrenia-associated genes.

Nature genetics·2026
Same author

Nephroprotective Effects of GLP-1 Receptor Agonists in Lithium-Treated Patients: A Multinational Cohort Study Using the TriNetX Network.

CNS spectrums·2026
Same author

Progress on Pharmacogenetic Tests for Antidepressant Drug Selection Requires Properly Designed Studies.

Journal of clinical psychopharmacology·2026
Same author

The American Society of Clinical Psychopharmacology task force consensus statement on the deprescribing of stimulant medications in adults with ADHD<sup>✰</sup>.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology·2026
Same author

Adjunctive Antipsychotics in Major Depressive Disorder: A Systematic Review and Network Meta-Analysis.

JAMA psychiatry·2026
Same author

Transdiagnostic Profiles of BOLD Signal Variability in Autism and Schizophrenia Spectrum Disorders: Associations With Cognition and Functioning.

Human brain mapping·2026

Genetic factors influence drug response in mood disorders. Pharmacogenetic studies suggest genotyping can improve treatment prediction and outcomes for patients.

Area of Science:

  • Psychiatry and Genetics
  • Pharmacogenomics
  • Molecular Psychiatry

Background:

  • Mood disorders often show variable responses to pharmacotherapy.
  • Genetic factors are increasingly recognized as potential contributors to treatment efficacy and adverse events.
  • Understanding these genetic underpinnings is crucial for personalized medicine.

Purpose of the Study:

  • To review recent molecular genetic studies on drug response in mood disorders.
  • To highlight the role of genetic mechanisms in predicting treatment outcomes.
  • To synthesize current evidence on pharmacogenetics in mood disorder management.

Main Methods:

  • Literature search of molecular genetic studies.
  • Analysis of pharmacogenetic findings related to drug response and adverse outcomes.

Related Experiment Videos

  • Review of studies investigating gene-environment interactions in mood disorders.

    • Main Results:

    • Pharmacogenetic studies generally report positive findings for genotyping in predicting treatment response.
    • Genotyping may enhance confidence in prospectively identifying treatment efficacy and adverse outcomes.
    • Specific genes related to receptors and signal transduction pathways show promise in predicting drug efficacy.

    Conclusions:

    • The body of evidence for genotype-based drug response in mood disorders is growing.
    • Genes involved in target receptors and signal transduction are potential predictors of treatment efficacy.
    • Further research into immediate early genes, mitochondrial genes, and epigenetics may yield additional predictors for bipolar disorder treatment.